New drug hope for lung damage after transplant falls short
NCT ID NCT04908735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improve lung function. Only 7 people enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States